365 related articles for article (PubMed ID: 25469833)
1. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
[TBL] [Abstract][Full Text] [Related]
2. A novel injectable phospholipid gel co-loaded with doxorubicin and bromotetrandrine for resistant breast cancer treatment by intratumoral injection.
Luo JW; Zhang T; Zhang Q; Cao X; Zeng X; Fu Y; Zhang ZR; Gong T
Colloids Surf B Biointerfaces; 2016 Apr; 140():538-547. PubMed ID: 26628333
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
5. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
6. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
7. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells.
Fu LW; Zhang YM; Liang YJ; Yang XP; Pan QC
Eur J Cancer; 2002 Feb; 38(3):418-26. PubMed ID: 11818209
[TBL] [Abstract][Full Text] [Related]
8. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
9. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
10. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
Chen LM; Liang YJ; Zhang X; Su XD; Dai CL; Wang FP; Yan YY; Tao LY; Fu LW
Anticancer Res; 2009 Nov; 29(11):4597-604. PubMed ID: 20032409
[TBL] [Abstract][Full Text] [Related]
12. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
13. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.
Jin J; Sun H; Wei H; Liu G
Invest New Drugs; 2007 Apr; 25(2):95-105. PubMed ID: 16937080
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
15. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
16. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
17. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
Zhang T; Luo J; Fu Y; Li H; Ding R; Gong T; Zhang Z
Colloids Surf B Biointerfaces; 2017 Feb; 150():89-97. PubMed ID: 27898360
[TBL] [Abstract][Full Text] [Related]
18. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin derivative loaded acetal-PEG-PCCL micelles for overcoming multidrug resistance in MCF-7/ADR cells.
Zhong XC; Xu WH; Wang ZT; Guo WW; Chen JJ; Guo NN; Wang TT; Lin MT; Zhang ZT; Lu YY; Yang QY; Han M; Xu DH; Gao JQ
Drug Dev Ind Pharm; 2019 Sep; 45(9):1556-1564. PubMed ID: 31271317
[No Abstract] [Full Text] [Related]
20. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]